menu
    • menu
    [{"orgOrder":0,"company":"Viriom","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viriom \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"15","companyTruncated":"Viriom \/ Russian Direct Investment Fund"},{"orgOrder":0,"company":"Viriom","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elsulfavirine","moa":"||NNRT","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viriom \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viriom \/ Inapplicable"},{"orgOrder":0,"company":"Viriom","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VM1500A","moa":"NNRT","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Viriom \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viriom \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Viriom

    Menu

    Viriom

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Viriom

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Viriom

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Favipiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Russian Direct Investment Fund

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Viriom and Chromis Publish Results of a Post-Marketing Clinical Study in 940 COVID-19 Patients Confirming Effi...

                            Details : The efficacy and safety of Avifavir was statistically significantly demonstrated in two Phase 2 and Phase 3 clinical trials in 460 medium severe and severely ill COVID-19 patients conducted between April and October 2020.

                            Product Name : Avifavir

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 03, 2021

                            Lead Product(s) : Favipiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Russian Direct Investment Fund

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Viriom

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Viriom

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elsulfavirine,Favipiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Viriom Initiates Phase 2 Clinical Study of Elsulfavirine for Treatment of COVID-19

                            Details : Phase 2 clinical study expands the ongoing research into elsulfavirine, which includes confirmation of elsulfavirine antiviral activity against COVID-19 infection by Zhejiang University in China.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 04, 2020

                            Lead Product(s) : Elsulfavirine,Favipiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Viriom

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Viriom

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VM1500A

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Viriom Initiates Phase 2 Study Investigating Efficacy of Intramuscular Long-Acting Injectable Nanoformulation ...

                            Details : Phase 2a study aims to select a therapeutic dose and assess safety and efficacy of VM-1500A-LAI multiple injections in HIV+ virally suppressed patients vs a marketed Elpida®-based once-daily regimen.

                            Product Name : VM1500A

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 05, 2020

                            Lead Product(s) : VM1500A

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth